Roberto S Accolla Selected Research

Histocompatibility Antigens Class II

1/2019	CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
3/2013	Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.
7/2012	Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines.
10/2010	CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
9/2010	New strategies of mammary cancer vaccination.
12/2007	Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer.
6/2006	CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
5/2003	Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberto S Accolla Research Topics

Disease

22	Neoplasms (Cancer) 01/2022 - 05/2003
4	Adenocarcinoma 06/2009 - 05/2003
3	Infections 01/2018 - 01/2017
3	Neuroblastoma 07/2010 - 10/2003
2	Leukemia 01/2022 - 01/2017
2	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2021 - 01/2016
2	Necrosis 03/2013 - 07/2010
2	Carcinoma (Carcinomatosis) 04/2006 - 05/2003
2	Fibrosarcoma 04/2006 - 05/2003
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Carcinogenesis 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 01/2017
1	Neglected Diseases 01/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2014
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2012
1	T-Cell Leukemia (Leukemia, T Cell) 08/2006
1	Virus Diseases (Viral Diseases) 04/2005

Drug/Important Bio-Agent (IBA)

8	Histocompatibility Antigens Class IIIBA 01/2019 - 05/2003
7	Neoplasm Antigens (Tumor Antigens)IBA 10/2020 - 06/2006
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2006
5	VaccinesIBA 01/2019 - 06/2006
5	MHC class II transactivator proteinIBA 10/2014 - 05/2003
4	Cancer VaccinesIBA 01/2022 - 03/2013
4	AntigensIBA 01/2021 - 07/2012
3	Peptides (Polypeptides)IBA 01/2022 - 05/2003
3	Trans-Activators (Trans-Acting Factor)IBA 01/2019 - 08/2006
3	Melphalan (Alkeran)FDA LinkGeneric 03/2013 - 04/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2010 - 04/2006
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 01/2012
2	CytokinesIBA 01/2018 - 04/2005
2	DNA (Deoxyribonucleic Acid)IBA 01/2012 - 12/2007
2	Therapeutic UsesIBA 07/2010 - 01/2005
2	Interleukin-12 (IL 12)IBA 12/2007 - 01/2005
2	Fibronectins (Fibronectin)IBA 12/2007 - 04/2006
1	Viral ProteinsIBA 01/2022
1	EpitopesIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 10/2020
1	Histocompatibility Antigens Class IIBA 01/2019
1	Protein Subunit VaccinesIBA 01/2019
1	AntibodiesIBA 01/2019
1	MitogensIBA 01/2018
1	env Gene ProductsIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Liposomes (Liposome)IBA 01/2017
1	Staphylococcal Protein A (Protein A)IBA 01/2017
1	Clodronic Acid (Clodronate)IBA 01/2017
1	factor AIBA 07/2015
1	ElementsIBA 03/2013
1	Cell ExtractsIBA 01/2012
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2012
1	PerforinIBA 01/2012
1	Interleukin-2 (IL2)IBA 07/2010
1	Biological ProductsIBA 12/2007
1	nuclear factor YIBA 08/2006
1	Interleukin-15 (Interleukin 15)IBA 01/2005
1	Complementary DNA (cDNA)IBA 10/2003
1	Messenger RNA (mRNA)IBA 10/2003
1	Interferon-gamma (Interferon, gamma)IBA 10/2003
1	3-hydroxy-5-estrane-17-carbonitrile (ACN)IBA 10/2003

Therapy/Procedure

9	Immunotherapy 01/2022 - 12/2007
5	Therapeutics 03/2013 - 01/2005
2	Drug Therapy (Chemotherapy) 03/2013 - 07/2012
2	Radiotherapy 03/2013 - 07/2012
1	Aftercare (After-Treatment) 12/2007